Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
NCT04074746Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AFM13 + cord blood-derived natural killer cells, acimtamig in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: completed.
02
Drugs
AFM13 + cord blood-derived natural killer cellsacimtamig
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)anaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT04074746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074746.